JPRN-UMIN000009182尚未招募未知
The effect of switching to Eldecalcitol from Alfacalcidol on osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer. - The effect of switching to Eldecalcitol from Alfacalcidol on osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Using other osteoporosis drugs except alfacalcidol within 6 months. 2. Patients suffered from malignancies except mammary carcinoma. 3. Patients with contraindication for eldecalcitol treatments 4. Patients who have serum calcium levels of above 10.4mg/dL. 5. Patients judged inappropriate by attending physicians.
研究者
相似试验
尚未招募
不适用
The comparison of Eldecalcitol and Alfacalcidol on early osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer.JPRN-UMIN000009183Kansai Medical University120
招募中
不适用
The study of effect of Alfacalcidol treatment on Crohn's diseases diseaseCrohn's diseaseJPRN-UMIN000025961agoya University Hospital31
已完成
不适用
The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosisJPRN-UMIN000007070Department of Hepatology, Osaka City University Graduate School of Medicine50
招募中
不适用
Switching from etelcalcetide to evocalcet in hemodialysis patients with secondary hyperparathyroidismSecondary hyperparathyroidismJPRN-UMIN000033856Jinken Clinic20
已完成
不适用
Quantitative assessment of the eldecalcitol effect on intestinal calcium absorptioPrimary osteoporosisJPRN-UMIN000020267Research secretariat (IDD, Inc.)40